Oncology Pharmacists Can Improve TKI Adherence Rates in Patients With CML
An oncology pharmacist-managed oral anticancer therapy program significantly improved tyrosine kinase inhibitor (TKI) adherence rates in patients with chronic myeloid leukemia (CML), a recent study published online ahead of print in the Journal of Oncology Pharmacy Practice has shown.
Because research has indicated that non-adherence is a major contributing factor for treatment failure in patients with CML receiving imatinib, oncology pharmacists at the Kaiser Permanente Health Plan Hematology Oncology Infusion Clinic in Antioch, CA, sought to evaluate the impact of an oncology pharmacist-managed program on oral medication adherence compared with usual care in patients with CML…
